Tissue engineering of the urethra: where are we in 2019?

Christopher Chapple

Received: 6 March 2019 / Accepted: 27 May 2019 / Published online: 12 June 2019
© The Author(s) 2019, corrected publication 2019

Abstract

Purpose The purpose of this review is to assess the potential role of tissue engineering for urethral reconstruction. It is well-recognised that urethrotomy remains the first-line therapy in the treatment of urethral stricture. Following on from the randomised study which recommended no difference between urethrotomy and urethral dilation, Steenkamp et al. reported long-term success rates of only 20%. Patients with longer strictures, penile or distal urethral strictures, and extensive perirethral spongiofibrosis typically do not respond well to repeated incisions. This report reviews the potential role of tissue engineering as applied to augmentation urethroplasty, which is the treatment of choice following failed urethrotomy.

Methods A review of the literature was carried out. The principal emphasis was on tissue engineering as applied to augmentation urethroplasty, but an introductory section reviews the use of urethrotomy and the background to contemporary practise with augmentation urethroplasty using oral mucosa.

Results It is evident that a cellular matrix which requires the ingrowth of cells is unlikely to be successful except for very short strictures. Other approaches such as injection of stem cells have not been adequately trialled in humans to date. Tissue-engineered substitute for autologous oral mucosa has been used and the results relating to this are reviewed.

Conclusions Tissue engineering of autologous tissue for urethroplasty is expensive. It is unnecessary for the majority of cases, but could be potentially useful for very lengthy strictures, for instance, relating to lichen sclerosis. Whilst tissue-engineered oral mucosa has been successfully used, a great deal more work would be necessary to develop an appropriate matrix. Another study has looked at a larger series using an alternative tissue-engineered substitute, but the results have been very disappointing. At present, it has to be concluded that there is no effective and validated tissue engineering solution for the management of urethral stricture disease.

Keywords Tissue engineering · Oral mucosa · Urethroplasty · Urethral stricture

Introduction

Urethrotomy remains the first-line therapy in the treatment of a urethral stricture. Following on from their randomised study which demonstrated no difference between urethrotomy and urethral dilatation, Steenkamp et al. [1, 2] reported long-term success rates of only 20%. Patients with longer (>2 cm in length), multiple, penile or distal strictures and extensive periurethral spongio-fibrosis typically did not respond well to repeated incisions. Thus, repeat internal urethrotomy offers no real chance of a cure after a third incision or if the stricture recurs within 3 months of the first incision. Such patients should be offered a urethroplasty—if a short stricture (<2 cm) an anastomotic procedure which has the highest chance of success, but failing this an augmentation procedure [3]. The intention of this paper is to review the potential for the use of tissue engineering in the management of urethral stricture disease. To do this, the surgical approaches are reviewed followed by an overview of the current evidence related to tissue engineering of the urethra in patients. The potential benefit of tissue engineering over the harvesting of autologous tissue is not needing to harvest the tissue, particularly when long lengths of urethra need to be augmented.
Beyond urethrotomy

Clearly the best form of tissue engineering would be to augment the healing process associated with an optical urethrotomy. A number of studies have evaluated the efficacy of agents injected into the scar tissue at the site of stricture area as part of an internal urethrotomy procedure to try and reduce recurrence rates by preventing recurrent spongiosis-fibrosis. Such agents include mitomycin C which has been used for anterior urethral stricture [4]. Authors have reported that after 15 months mean follow-up urethral stricture recurred in 10% of patients in the mitomycin C treated group and in 50% of patients in the untreated group [5]. Another study evaluated the use of triamcinolone injection and showed a significant decrease in recurrence rate [6, 7].

A potential approach is to obtain autologous urothelial or other mature stem cells and use these to augment an urethrotomy. Systematic review of the world literature on this subject concluded that there are a number of regulatory and other technical hurdles which have yet to be overcome before considering this in clinical practice [8–11].

Clearly if an anastomotic urethroplasty is not possible then an augmentation procedure becomes necessary. Currently, grafts are favoured over flaps, since although outcomes are similar, flaps are associated with a far greater likelihood of graft site morbidity. A range of materials have been used for urethral grafting including originally penile and scrotal skin which were historically extensively used along with non-genital skin. All of these materials, in particular scrotal skin do carry a high restenosis rate as all are skin types which do not respond well to a wet environment. Additionally, scrotal skin suffers the disadvantage of containing hair follicles which are difficult to successfully remove, leading to the formation of hair in the neo-urethra. Because of these disadvantages the use of ‘wet’ mucosa has been explored leading to the use of oral mucosa, bladder mucosa, and colonic mucosa. Among the tissues successfully used for augmentation urethroplasty, oral mucosa has increasingly gained popularity over the last decade, as it is easy to harvest with low morbidity and does not necessitate invasive surgery. Whilst Humby is often credited with being the first surgeon to describe an oral mucosal graft to augment a strictured urethra in 1941 [12], it is now clear that its first use was described at the end of the nineteenth century by the Russian surgeon Kirill Sapezhko, who reported a series of four cases [13]. Oral mucosa is particularly useful as it represents a ‘wet’ mucosal surface which adapts well to the moist environment of the urethra and is particularly resistant to balanitis xerotica obliterans (BXO). The most equivalent material which has been described for urethroplasty is bladder mucosa, but this requires an invasive approach for its harvesting. It is now widely accepted that the long-term results obtained with the use of penile skin are inferior to oral mucosa and its use is contraindicated in any patients with BXO. Nobody would now dispute the view that scrotal skin is definitely best avoided as the long-term results seen with this ‘dry’ skin are far inferior, because of its propensity to hair bearing and the inevitable transplantation of hair follicles into any reconstruction. The only other major debate in this field of reconstruction relates to whether grafts or flaps of tissue provide superior results. Whilst the results are comparable there is more morbidity seen with flaps [14].

Tissue engineering

Tissue engineering could be an effective way of facilitating reconstruction without the need for harvesting tissue by generating a bioengineered solution. The options include the use of acellular matrices, seeding cells into a damaged urethra or the implantation of a newly engineered substitute.

Acellular scaffolds have been reported in preclinical studies and certainly enjoyed a vogue. The major problem with this approach is that it is dependent upon the ingrowth of cells. The first material that was reported in preclinical trials was small intestine submucosa (SIS). However, not surprisingly SIS has limited effectiveness when used without stem cell seeding [15, 16]. An organ-specific acellular matrix is another graft option for urethral reconstruction. Urethral acellular matrix (UAM) is collected from the donor, decellularised and the recipient’s urethra is substituted by transplantation. Good results were observed when homologous transplantation was performed. Complete epithelialisation was achieved, and smooth muscle bundles regenerated spontaneously [17]. UAM has been used in clinical experiments with a success rate between 75 and 100% [18]. Another approach was the use of acellular bladder matrix (ABM) harvested from porcine or loparine bladder and seeded with autologous oral keratinocytes, adipose-derived stem cells, autologous bladder smooth muscle cells and urothelial cells [19, 20] and likewise, acellular bladder submucosa matrix (BSM) seeded with autologous minced urethral tissue linked to BSM with fibrin glue [21]. More recently, the use of urine-derived stem cells in a rabbit model has been reported with the potential for this being of value for future research in this area [22]. Translation of these techniques from basic experiments to clinical experience poses numerous challenges for the future. Preclinical data are based on different animal models (rabbit, rat and dog) and various types of injury, none of which accurately mimic the pathological situation seen with a true stricture where there is a full thickness ischaemic spongiosis-fibrosis. Whilst there have been limited clinical trials, none of these have provided adequate objective long-term follow-up or led to more widespread adoption of the results.
A report in humans of 50 patients using small intestinal submucosa without cell seeding [23] showed after a mean follow-up of 31.2 months (range 24–36 months) the excellent clinical, radiological, and cosmetic findings in 40 (80%) patients. Re-strictures developed in 1 of 10 bulbar, 5 of 31 bulbopenisile, and 4 of 9 penile strictures. These all occurred in the first 6 months post-operatively. A randomised controlled trial comparing an acellular matrix with oral mucosa has also been reported [24]. Human demineralized bone matrix, obtained from cadaveric donors, was processed and prepared for use as an off-the-shelf material. 30 patients with stricture 21–59 years old (mean 36.2) were enrolled and assessed using a standard protocol. The stricture length ranged from 2 to 18 cm (mean 6.9), of which 11 patients had bulbar, 7 had pendulous and 12 had combined bulbopendulous strictures. All patients except two who were lost during follow-up were followed for 18–36 months (mean 25). In patients with a healthy urethral bed (less than two prior operations), the success rate of buccal mucosa grafts (10 of 10) was similar to the bladder matrix grafts (8 of 9) in terms of patency. In patients with an unhealthy urethral bed (more than two prior operations), only two of six patients with a bladder matrix graft were successful, whereas all five patients with a buccal mucosa graft had a patent urethra. At this time, whilst the results of these studies are of considerable interest, further information in terms of longer follow-up with objective assessment is essential before these data would lead to more widespread adoption of these techniques into routine clinical practice.

We established a programme to evaluate the potential for bio-engineering oral mucosa, because of the cases which we treat with full-length urethral strictures usually consequent upon lichen sclerosis of the urethra, where it can be difficult to be able to harvest an adequate amount of oral mucosa. In 2008, we reported the first use of tissue-engineered oral mucosa for augmentation urethroplasty in five patients. We found when used as an open graft as the first stage of a two-stage procedure of the penile urethra, that the initial results were good in all five patients with rapid vascularisation of the graft [25]. In this study, all the patients had lengthy strictures with the same aetiology, namely lichen sclerosis. Retubularisation of all five patients occurred as though native buccal mucosa had been used. However, after 8 and 9 months, respectively, two of the five patients’ grafts developed contraction and fibrosis. One graft was completely removed and one partially removed and replaced by native buccal mucosa. Histology of the two excised grafts showed pronounced epithelial hyperproliferation and fibrosis [26]. Careful follow-up and a recent 9-year follow-up in 2014 showed no stricture progression in the four patients followed up and endoscopically the mucosa was still in place and macroscopically normal [26–28]. In view of these mixed clinical results, we decided to undertake further investigation into the mechanism of contraction of tissue-engineered bladder mucosa in vitro before going forward clinically. After careful reflection, we decided in view of the ease of harvesting oral mucosa, the limited number of cases which required more than 15 cm of augmentation and the high cost of such an approach, and did not continue the project.

A new bioengineered material was reported 3 years later, in an observational study of five boys with urethral defects of length 4–6 cm with a follow-up ranging from 36 to 76 months post-operatively, using polyactic-co-glycolide (PLGA), seeded with autologous bladder smooth muscle and urothelial cells, and prepared as tubularised grafts. The median age was 11 years (range 10–14) at the time of surgery and median follow-up was 71 months (range 36–76 months. The median end maximum urinary flow rate was 27.1 mL/s (range 16–28), and serial radiographic and endoscopic studies showed the maintenance of wide urethral calibres without strictures. Urethral biopsies showed that the engineered grafts had developed a normal appearing architecture by 3 months after implantation [29]. These excellent data are more positive than seen in contemporary clinical experience using a tubularised autologous oral mucosal graft.

The most important factors in assessing the outcome of a new tissue engineering procedure is careful background basic research, the appropriate use of animal models [30, 31] and the comprehensive long-term follow-up of patients. A further important issue is the increased recognition in recent years that when cells, particularly stem cells, are harvested and placed in a new tissue environment then they can change their phenotype. There are clearly a number of challenges in particular when bioengineering technology is applied to organs such as the trachea. After initial optimism [32], a more measured and reflective approach has been adopted consequent upon complications seen with the clinical application of this technology [33, 34].

The importance of a carefully preclinical and clinical evaluation of any tissue-engineered oral mucosal product before it is introduced into practice has been emphasised [35, 36]. These authors highlighted the challenges associated with introducing a tissue-engineered product into clinical practice and reviewed what they felt to be the relevant regulatory challenges in Europe [37]. Clinical co-workers allied with this group expressed enthusiasm for this new material [38] and cited the results of this initial study in support of this view. In this initial series of patients (n = 21) with a median follow-up of 18 months (range 13–22), the success rate reported was 80.9%. This study represents the most important step in the clinical use of tissue-engineered material for urethral reconstruction [37]. Barbagli and Lazzini concluded ‘that by following strict protocol criteria, it is possible to move tissue-engineering technology from the laboratory bench to the bedside’. They did, however, emphasise the importance of an appropriate subsequent
study and were justified in taking a cautious approach as the subsequent larger prospective observational multicentre clinical study of 99 patients from eight centres Subsequently showed from this group [39]. They reported success with a heavy reliance on subjective measures and flow rates at 2 years in 98 patients. There was significant variation in the results between different centres, with two low-volume centres reporting success rates of 0% and 50%, respectively, at 1 year with an overall success rate of 67.3% and a 2-year success rate of approximately 60%. From a careful review of this paper, it is in my view likely if urethrography or urethroscopy had been carried out in all of the cases the success rate is likely to have been lower than this. This is clearly less than the success rates noted in a systematic review of more than 2000 anterior urethroplasty procedures described in the literature. For bulbar urethral strictures, there was no significant difference between the average success rates of the dorsal and the ventral onlay procedures, 88.4% and 88.8% at 42.2 and 34.4 months in 934 and 563 patients, respectively [40].

Conclusion

Urethral strictures are common and management of long-segment strictures present a ongoing challenging surgical problem primarily because of stricture recurrence following urethrotomy or urethral dilatation. This is an area where much more research is needed and we would conclude that it is an area of unmet clinical need where users of tissue engineering in the future need to carry out a rigorous basic science programme and need to be cautious in drawing conclusions based on initial experience and report on long-term clinical results.

Compliance with ethical standards

Conflict of interest I have worked extensively with the pharmaceutical industry, none of the conflicts relate to this topic. I have been involved in the development of bio-engineered alternative to conventional synthetic sliг materials with Symmεtic Μtd.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Steenkamp JW, Heyns CF, de Kock ML (1997) Internal urethrotomy versus dilation as treatment for male urethral strictures: a prospective, randomized comparison. J Urol 157:98–101
2. Heyns CF, Steenkamp JW, De Kock ML, Whitaker P (1998) Treatment of male urethral strictures: is repeated dilation or internal urethrotomy useful? J Urol 160:356–358
3. Chapple C, Andrich D, Atala A, Barbagli G, Cavalcanti A, Kulkarni S, Nakajima Y, Mangera A (2014) SIU/ICUD consultation on urethral strictures: the management of anterior urethral stricture disease using substitution urethropathy. Urology 83(3):S31–S47
4. Park JJ, Kuo TL, Chapple CR (2018) Mitomycin C in the treatment of anterior urethral strictures. Nat Rev Urol 15(12):717–71824
5. Mazdak H, Meshiki I, Ghassami F (2007) Effect of mitomycin C on anterior urethral stricture recurrence after internal urethrotomy. Eur Urol 51:1089–1092 (discussion 92)
6. Tavakkoli Tabassi K, Yarmohamadi A, Mohammadi S (2011) Triamcinolone injection following internal urethrotomy for treatment of urethral stricture. Urol J 8:132–136
7. Mazdak H, Izadpanahi MH, Ghalamkari A, Kabiri M, Khorrami MH, Nouri-Mahdavi K et al (2010) Internal urethrotomy and intraurethral submucosal injection of triamcinolone in short bulbar urethral strictures. Int Urol Nephrol 42:565–568
8. de Kemp V, de Graaf P, Flederus JO, Ruud Bosch JL, de Kort LM (2015) Tissue engineering for human urethral reconstruction: systematic review of recent literature. PLoS One 10:2
9. Fu Q, Cao YL (2012) Tissue engineering and stem cell application of urethropathy: from bench to bedside. Urology 79(2):246–253
10. Xue JD, Gao J, Fu Q, Feng C, Xie H (2016) Seeding cell approach for tissue-engineered urethral reconstruction in animal study: a systematic review and meta-analysis. Exp Biol Med (Maywood) 241(13):1416–1428
11. Versteegden LRM, de Jonge PKJD, InthHout J, van Kuppevelt TH, Oosterwijk E, Feitz WFI, de Vries RBM, Daamen WF (2017) Tissue engineering of the urethra: a systematic review and meta-analysis of preclinical and clinical studies. Eur Urol 72(4):594–606
12. Humby G (1941) A one-stage operation for hypospadias. Br J Surg 29:84–92
13. Korneyev I, Ilyin D, Schultheiss D, Chapple C (2012) The first oral mucosal graft urethropathy was carried out in the 19th century: the pioneering experience of Kirill Sapezhko (1857–1928). Eur Urol 62(4):624–627
14. Dubey D, Vijjan V, Kapoor R, Srivastava A, Mandhani A, Kumar A, Ansari MS (2007) Dorsal onlay buccal mucosa versus penile skin flap urethropathy for anterior urethral strictures: results from a randomized prospective trial. J Urol 178(6):2466–2469
15. Chao L, Yue-Min X, Lu-Jie S, Qiang F, Lei C (2008) Urethral reconstruction using oral keratinocyte seeded bladder acellular matrix grafts. J Urol 180(4):1538–1544
16. Dorin RP, Pohl HG, De Filippo RE, Yoo JJ, Atala A (2008) Tubularized urethral replacement with unseeded matrices: what is the maximum distance for normal tissue regeneration. World J Urol 26:323–326
17. Sievert KD et al (2001) Heterologous acellular matrix graft for reconstruction of the rabbit urethra: histological and functional evaluation. J Urol 165(6):2096–2102
18. Ribeiro-Filho LA, Sievert KD (2015) Acellular matrix in urethral reconstruction. Adv Drug Deliv Rev 82–83:38–46
19. Liao W, Yang S, Song C, Li X, Li Y, Xiong Y (2013) Construction of urethral grafts by seeding bone marrow mesenchymal stem cells and smooth muscle cells into bladder acellular matrix. Transplant Proc 45(2):730–734

Springer
20. De Filippo RE, Yoo JJ, Atala A (2002) Urethral replacement using cell seeded tubularized collagen matrices. J Urol 168:1789–1792 (discussion 1792–3)

21. Chun SY, Kim BS, Kwon SY et al (2015) Urethroplasty using autologous urethral tissue-embedded acellular porcine bladder submucosa matrix grafts for the management of long-segment urethral stricture in a rabbit model. J Korean Med Sci 30(3):301–307

22. Yang H, Chen B, Deng J, Zhuang G, Wu S, Liu G, Deng C, Yang G, Qiu X, Wei P, Wang X, Zhang Y (2018) Characterization of rabbit urine-derived stem cells for potential application in lower urinary tract tissue regeneration. Cell Tissue Res 374(2):303–315

23. Fiala R et al (2007) Porcine small intestinal submucosa graft for repair of anterior urethral strictures. Eur Urol 51(6):1702–1708

24. El Kassaby AW et al (2008) Randomized comparative study between buccal mucosal and acellular bladder matrix grafts in complex anterior urethral strictures. J Urol 179(4):1432–1436

25. Bhargava S, Patterson JM, Inman RD, MacNeil S, Chapple CR (2008) Tissue-engineered buccal mucosa urethroplasty-clinical outcomes. Eur Urol 53(6):1263–1269

26. Patterson JM, Bullock AJ, MacNeil S, Chapple CR (2011) Methods to reduce the contraction of tissue-engineered buccal mucosa for use in substitution urethroplasty. Eur Urol 60:856–861

27. Osman NI, Patterson JM, MacNeil S, Chapple CR (2014) Long-term follow-up after tissue-engineered buccal mucosa urethroplasty. Eur Urol 66:790–791

28. Simsek A, Aldamanhorı R, Chapple CR, MacNeil S (2018) Overcoming scarring in the urethra: challenges for tissue engineering. Asian J Urol 5(2):69–77

29. Raya Rivera A, Esquiliano DR, Yoo JJ, Lopez-Bayghen E, Soker S, Atala A (2011) Tissue-engineered autologous urethras for patients who need reconstruction: an observational study. Lancet 377(9772):1175–1182. https://doi.org/10.1016/S0140-6736(10)62354-9

30. Kajbafzadeh AM, Abbasioun R, Sabetkish S, Sabetkish N, Rahmani P, Tavakkolitabassi K, Arshadi H (2017) Future prospects for human tissue engineered urethra transplantation: decellularization and recellularization-based urethra regeneration. Ann Biomed Eng 45(7):1795–1806

31. Sievert KD (2017) Tissue engineering of the urethra: solid basic research and farsighted planning are required for clinical application. Eur Urol 72(4):607–609

32. Laurance J (2008) Martin Birchall: using stem cells to help make transplant history. Lancet 372(9656):2104

33. Weiss DJ, Elliott M, Jang Q, Poole B, Birchall M, International Society of Cell Therapy Pulmonary Scientific Committee (2014) Tracheal bioengineering: the next steps. Proceedings of an International Society of Cell Therapy Pulmonary Cellular Therapy Signature Series Workshop, Paris, France, April 22. Cytotherapy 16(12):1601–1613

34. Hawkes N (2018) Academics who raised concerns about research misconduct are threatened with lawsuit. BMJ 362:k3100

35. Ram-Liebig G, Meye A, Hakenberg OW, Haase M, Baretton G, Wirth MP (2004) Induction of proliferation and differentiation of cultured urothelial cells on acellular biomaterials. BJU Int 94(6):922–927

36. Ram-Liebig G, Ravens U, Balana B, Haase M, Baretton G, Wirth MP (2006) New approaches in the modulation of bladder smooth muscle cells on viable detrusor constructs. World J Urol 24(4):429–437

37. Ram-Liebig G, Bednarz J, Stuerzebecher B, Fahlenkamp D, Barbagli G, Romano G, Balsmeyer U, Spiegeler ME, Liebig S, Knispel H (2015) Regulatory challenges for autologous tissue engineered products on their way from bench to bedside in Europe. Adv Drug Deliv Rev 82–83:181–191

38. Barbagli G, Lazzéri M (2015) Clinical experience with urethral reconstruction using tissue-engineered oral mucosa: a quiet revolution. Eur Urol 68(6):917–918

39. Ram-Liebig G, Barbagli G, Heidenreich A, Fahlenkamp D, Romano G, Rehmann U, Standhaft D, van Ahlen H, Schakaki S, Balsmeyer U, Spiegler M, Knispel H (2017) Results of use of tissue-engineered autologous oral mucosa graft for urethral reconstruction: a multicenter, prospective, observational trial. EBioMedicine 23:185–192

40. Mangera A, Patterson JM, Chapple CR (2011) A systematic review of graft augmentation urethroplasty techniques for the treatment of anterior urethral strictures. Eur Urol 59(5):797–814

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.